AFC
MRNA icon

AFT Forsyth & Company’s Moderna MRNA Stock Holding History

AFT Forsyth & Company’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,158
Closed -$613K – 136
2024
Q2 		$613K Hold
5,158
– – 0.3% 73
2024
Q1 		$550K Sell
5,158
-20
-0.4% -$2.02K 0.31% 78
2023
Q4 		$515K Buy
5,178
+1,533
+42% +$129K 0.32% 79
2023
Q3 		$376K Buy
3,645
+580
+19% +$64.7K 0.28% 93
2023
Q2 		$372K Sell
3,065
-125
-4% -$16.7K 0.26% 95
2023
Q1 		$490K Buy
3,190
+25
+0.8% +$4.12K 0.38% 78
2022
Q4 		$568K Hold
3,165
– – 0.48% 62
2022
Q3 		$374K Hold
3,165
– – 0.33% 91
2022
Q2 		$452K Sell
3,165
-50
-2% -$7.15K 0.36% 82
2022
Q1 		$554K Sell
3,215
-1,845
-36% -$311K 0.35% 82
2021
Q4 		$1.28M Hold
5,060
– – 0.66% 48
2021
Q3 		$1.95M Buy
5,060
+50
+1% +$18.4K 1.05% 22
2021
Q2 		$1.18M Buy
+5,010
New +$895K 0.63% 48

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AFT Forsyth & Company's MRNA Position: Q3 2024 in Review

AFT Forsyth & Company sold out of Moderna (MRNA) in Q3 2024, closing a stake of 5,158 shares — an estimated $613K sold.

AFT Forsyth & Company first reported a position in MRNA in Q2 2021 and held it in 13 quarters. The position peaked at $1.95M in Q3 2021. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • AFT Forsyth & Company reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • AFT Forsyth & Company sold 5,158 Moderna shares in Q3 2024, an estimated $613K.
  • AFT Forsyth & Company first reported a position in Moderna in Q2 2021 and held it in 13 quarters.
  • AFT Forsyth & Company's Moderna position peaked at $1.95M in Q3 2021.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on AFT Forsyth & Company's 13F filing for Q3 2024, filed 14 Nov 2024.